AAAAAA
Results: 1-25/33
Authors:
Tasch, J
Gong, M
Sadelain, M
Heston, WDW
Citation: J. Tasch et al., A unique folate hydrolase, prostate-specific membrane antigen (PSMA): A target for immunotherapy?, CR R IMMUN, 21(1-3), 2001, pp. 249-261
Authors:
Bacich, DJ
Pinto, JT
Tong, WP
Heston, WDW
Citation: Dj. Bacich et al., Cloning, expression, genomic localization, and enzymatic activities of themouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase, MAMM GENOME, 12(2), 2001, pp. 117-123
Authors:
Cozzi, PJ
Malhotra, S
Mcauliffe, P
Kooby, DA
Federoff, HJ
Huryk, B
Johnson, P
Scardino, PT
Heston, WDW
Fong, Y
Citation: Pj. Cozzi et al., Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model, FASEB J, 15(7), 2001, pp. 1306-1308
Authors:
Watt, F
Martorana, A
Brookes, DE
Ho, T
Kingsley, E
O'Keefe, DS
Russell, PJ
Heston, WDW
Molloy, PL
Citation: F. Watt et al., A tissue-specific enhancer of the prostate-specific membrane antigen gene,FOLH1, GENOMICS, 73(3), 2001, pp. 243-254
Authors:
Carroll, PR
Fair, WR
Grossfeld, GD
Heston, WDW
Lieberman, R
Malkowicz, SB
Stricker, HJ
Sylvester, J
Peehl, DM
Meyer, F
Hart, C
Citation: Pr. Carroll et al., Overview consensus statement, UROLOGY, 58(2A), 2001, pp. 1-4
Authors:
Fair, WR
Stricker, HJ
Lieberman, R
Bubley, GJ
Trachtenberg, J
Heston, WDW
Citation: Wr. Fair et al., Discussion following Dr. Hans J. Stricker's presentations, UROLOGY, 58(2A), 2001, pp. 27-27
Authors:
Daniell, HW
Chen, S
Fair, WR
Heston, WDW
Pirani, JF
Bubley, GJ
Carroll, PR
Gleave, ME
Citation: Hw. Daniell et al., Discussion following Dr. Sophie Chen's (pages 28-35) and Dr. John F. Pirani's presentations, UROLOGY, 58(2A), 2001, pp. 38-38
Authors:
Fair, WR
Newling, DWW
Heston, WDW
Trachtenberg, J
Malkowicz, SB
Gleave, ME
Citation: Wr. Fair et al., The role of diethylstilbestrol in the treatment of prostate cancer - Discussion, UROLOGY, 58(2A), 2001, pp. 113-113
Authors:
Uchida, A
O'Keefe, DS
Bacich, DJ
Molloy, PL
Heston, WDW
Citation: A. Uchida et al., In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: A potential alternative approach toandrogen deprivation therapy, UROLOGY, 58(2A), 2001, pp. 132-139
Authors:
Chang, SS
Reuter, VE
Heston, WDW
Gaudin, PB
Citation: Ss. Chang et al., Comparison of anti-prostate-specific membrane antigen antibodies and otherimmunomarkers in metastatic prostate carcinoma, UROLOGY, 57(6), 2001, pp. 1179-1183
Authors:
Chang, SS
Reuter, VE
Heston, WDW
Gaudin, PB
Citation: Ss. Chang et al., Metastatic renal cell carcinoma neovasculature expresses prostate-specificmembrane antigen, UROLOGY, 57(4), 2001, pp. 801-805
Authors:
O'Keefe, DS
Bacich, DJ
Heston, WDW
Citation: Ds. O'Keefe et al., Prostate specific membrane antigen, CONT CANC R, 2001, pp. 307-326
Authors:
Gong, MC
Chang, SS
Watt, F
O'Keefe, DS
Bacich, DJ
Uchida, A
Bander, NH
Reuter, VE
Gaudin, PB
Molloy, PL
Sadelian, M
Heston, WDW
Citation: Mc. Gong et al., Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy, MOL UROL, 4(3), 2000, pp. 217-222
Authors:
Howell, S
Heston, WDW
Sakr, W
Bostwick, D
Bruchovsky, N
Garnick, M
Stone, N
Garzotto, M
Citation: S. Howell et al., Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy - Open discussion following Dr. Heston's presentation, MOL UROL, 4(3), 2000, pp. 223-223
Authors:
Larchian, WA
Horiguchi, Y
Nair, SK
Fair, WR
Heston, WDW
Gilboa, E
Citation: Wa. Larchian et al., Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: A liposome-mediated gene therapy treatment for bladder cancer, CLIN CANC R, 6(7), 2000, pp. 2913-2920
Authors:
Kelly, WK
Osman, I
Reuter, VE
Curley, T
Heston, WDW
Nanus, DM
Scher, HI
Citation: Wk. Kelly et al., The development of biologic end points in patients treated with differentiation agents: An experience of retinoids in prostate cancer, CLIN CANC R, 6(3), 2000, pp. 838-846
Authors:
Horiguchi, Y
Larchian, WA
Kaplinsky, R
Fair, WR
Heston, WDW
Citation: Y. Horiguchi et al., Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model, GENE THER, 7(10), 2000, pp. 844-851
Authors:
Pinto, JT
Qiao, CH
Xing, J
Suffoletto, BP
Schubert, KB
Rivlin, RS
Huryk, RF
Bacich, DJ
Heston, WDW
Citation: Jt. Pinto et al., Alterations of prostate biomarker expression and testosterone utilization in human LNCaP prostatic carcinoma cells by garlic-derived S-allylmercaptocysteine, PROSTATE, 45(4), 2000, pp. 304-314
Authors:
O'Keefe, DS
Uchida, A
Bacich, DJ
Watt, FB
Martorana, A
Molloy, PL
Heston, WDW
Citation: Ds. O'Keefe et al., Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer, PROSTATE, 45(2), 2000, pp. 149-157
Authors:
Chang, SS
Gaudin, PB
Reuter, VE
Heston, WDW
Citation: Ss. Chang et al., Prostate-specific membrane antigen: Present and future application, UROLOGY, 55(5), 2000, pp. 622-629
Authors:
Chang, SS
Reuter, VE
Heston, WDW
Hutchinson, B
Grauer, LS
Gaudin, PB
Citation: Ss. Chang et al., Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues, CANCER, 88(2), 2000, pp. 407-415
Authors:
Chang, SS
Gaudin, PB
Reuter, VE
O'Keefe, DS
Bacich, DJ
Heston, WDW
Citation: Ss. Chang et al., Prostate-specific membrane antigen: Much more than a prostate cancer marker, MOL UROL, 3(3), 1999, pp. 313-319
Authors:
Cozzi, PJ
Bajorin, DF
Tong, W
Nguyen, H
Scott, J
Heston, WDW
Dalbagni, G
Citation: Pj. Cozzi et al., Toxicology and pharmacokinetics of intravesical gemcitabine: A preclinicalstudy in dogs, CLIN CANC R, 5(9), 1999, pp. 2629-2637
Authors:
Chang, SS
O'Keefe, DS
Bacich, DJ
Reuter, VE
Heston, WDW
Gaudin, PB
Citation: Ss. Chang et al., Prostate-specific membrane antigen is produced in tumor-associated neovasculature, CLIN CANC R, 5(10), 1999, pp. 2674-2681
Authors:
Gong, MC
Chang, SS
Sadelain, M
Bander, NH
Heston, WDW
Citation: Mc. Gong et al., Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers, CANC METAST, 18(4), 1999, pp. 483-490